

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

203389Orig1s000

Trade Name: PROCYSBI

Generic Name: (cysteamine bitartrate) delayed-release capsules, for oral use

Sponsor: Raptor Therapeutics, Inc.

Approval Date: April 30, 2013

Indications: Procysbi is a cystine depleting agent indicated for the management of nephropathic cystinosis in adults and children ages 6 years and older.

CENTER FOR DRUG EVALUATION AND RESEARCH

203389Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Summary Review	X
Officer/Employee List	X
Office Director Memo	
Cross Discipline Team Leader Review	X
Medical Review(s)	X
Chemistry Review(s)	X
Environmental Assessment	
Pharmacology Review(s)	X
Statistical Review(s)	X
Microbiology Review(s)	
Clinical Pharmacology/Biopharmaceutics Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

203389Orig1s000

APPROVAL LETTER



NDA 203389

NDA APPROVAL

Raptor Therapeutics, Inc.
Attention: Yvonne Kim
Director, Regulatory Affairs
9 Commercial Boulevard, Suite 200
Novato, CA 94949

Dear Ms. Kim:

Please refer to your New Drug Application (NDA) dated and received March 30, 2012, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for PROCYSBI (cysteamine bitartrate) Delayed-Release Capsules, 25 mg and 75 mg.

We acknowledge receipt of your amendments dated April 9 and 30, 2012; May 29, 2012; June 26, 2012; July 18 and 25, 2012; August 7 and 22, 2012; September 5 and 7, 2012; October 5, 9, 16, 17 and 26, 2012; November 1, 19, 26, and 30(2), 2012; December 6, 14, 20, and 21, 2012; January 8, 28 and 30, 2013; February 13 and 20, 2013; March 29, 2013; and April 23, 24 and 29, 2013.

This new drug application provides for the use of PROCYSBI (cysteamine bitartrate) Delayed-Release Capsules, 25 mg and 75 mg for the treatment of nephropathic cystinosis in adults and children age 6 years and older.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and patient package insert). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE-CONTAINER LABELS

We acknowledge your April 24, 2013, submission containing final printed container labels.

ADVISORY COMMITTEE

Your application for PROCYSBI (cysteamine bitartrate) Delayed-Release Capsules was not referred to an FDA advisory committee because this drug is not first in class; the application did not raise significant safety or efficacy issues that were unexpected for a drug of this class; outside expertise was not necessary and there were no controversial issues that would benefit from advisory committee discussion.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitments:

2043-1 Revise the drug product specification to add testing of elemental impurities for ^{(b) (4)} per USP <232>.

The timetable you submitted on March 4, 2013, states that you will provide this information according to the following schedule:

Final Report Submission: 06/2013

Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled “**Postmarketing Commitment Protocol**,” “**Postmarketing Commitment Final Report**,” or “**Postmarketing Commitment Correspondence**.”

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

We acknowledge receipt of your submission dated March 30, 2012, of a proposed risk evaluation and mitigation strategy (REMS). We have determined that, at this time, a REMS is not necessary for PROCYSBI (cysteamine bitartrate) Delayed-Release Capsules to ensure that its benefits outweigh its risks. We will notify you if we become aware of new safety information and make a determination that a REMS is necessary.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Jessica Benjamin, Regulatory Project Manager, at (301) 796-3924.

Sincerely,

{See appended electronic signature page}

Andrew E. Mulberg, M.D., FAAP, CPI
Deputy Director
Division of Gastroenterology and Inborn
Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure(s):
Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ANDREW E MULBERG
04/30/2013